Ronald Hoffman

Q: What Schools Are Affiliated With Ronald Hoffman

Ronald Hoffman is affiliated with the following schools: University of Illinois Chicago, University of Arkansas for Medical Sciences, Yale University, Medical College of Wisconsin, Icahn School of Medicine at Mount Sinai, University of Illinois College of Medicine, Baylor College of Medicine

Ronald Hoffman's AcademicInfluence.com Rankings

Ronald Hoffman

Philosophy

#4101

World Rank

#6492

Historical Rank

Logic

#1637

World Rank

#2439

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ronald Hoffman's Degrees

Doctorate Medicine Stanford University

Why Is Ronald Hoffman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronald Hoffman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. (2002) (2280)
Hematology: Basic Principles and Practice (1995) (1475)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. (2003) (725)
The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. (1986) (513)
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. (2001) (462)
A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. (1979) (393)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. (1989) (326)
Role of members of the Wnt gene family in human hematopoiesis. (1998) (316)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. (2013) (269)
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. (2003) (250)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. (2022) (249)
Suppression of erythroid-colony formation by lymphocytes from patients with aplastic anemia. (1977) (247)
Regulation of megakaryocytopoiesis. (1989) (237)
Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. (1988) (210)
Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. (1992) (210)
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. (1996) (204)
Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 10(-7). (1995) (202)
Human CD34(+) stem cells express the hiwi gene, a human homologue of the Drosophila gene piwi. (2001) (201)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. (2005) (199)
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. (2004) (198)
The renaissance of interferon therapy for the treatment of myeloid malignancies. (2011) (196)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial (2018) (193)
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. (2007) (190)
Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. (1990) (173)
Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. (2001) (163)
Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. (1990) (163)
Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. (1977) (163)
Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. (1981) (162)
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. (2000) (160)
The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. (2010) (160)
The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. (2009) (157)
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. (2006) (156)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis (2012) (155)
Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. (1991) (151)
Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells. (1995) (150)
Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. (1991) (149)
Embryonic-fetal erythroid characteristics of a human leukemic cell line. (1980) (148)
Growth factors affecting human thrombocytopoiesis: potential agents for the treatment of thrombocytopenia. (1992) (145)
Effect of c-kit ligand on in vitro human megakaryocytopoiesis. (1991) (144)
Effect of interleukin 6 on in vitro human megakaryocytopoiesis: its interaction with other cytokines. (1989) (143)
Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. (1993) (141)
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (2002) (140)
Interacting cytokines regulate in vitro human megakaryocytopoiesis. (1989) (140)
Diamond-Blackfan syndrome: lymphocyte-mediated suppression of erythropoiesis. (1976) (138)
Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. (1988) (136)
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. (2014) (132)
Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. (1994) (130)
Human hematopoietic stem cell adherence to cytokines and matrix molecules. (1992) (130)
Excessive zinc ingestion. A reversible cause of sideroblastic anemia and bone marrow depression. (1990) (130)
Epigenetic reprogramming induces the expansion of cord blood stem cells. (2014) (125)
Characterization of the human burst-forming unit-megakaryocyte. (1989) (124)
Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies. (1981) (120)
A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. (1995) (120)
Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor. (1992) (120)
T cell chronic lymphocytic leukemia: presence in bone marrow and peripheral blood of cells that suppress erythropoiesis in vitro. (1978) (118)
Persistence of human multilineage, self-renewing lymphohematopoietic stem cells in chimeric sheep. (1993) (115)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. (2015) (114)
Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. (1994) (112)
Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. (1998) (111)
The relative quiescence of hematopoietic stem cells in nonhuman primates. (2001) (109)
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. (2005) (105)
Sustained human hematopoiesis in sheep transplanted in utero during early gestation with fractionated adult human bone marrow cells. (1992) (103)
Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. (1987) (100)
Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea. (2019) (99)
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. (2012) (98)
Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential. (2007) (96)
Role of Members of the Wnt Gene Family in Human Hematopoiesis (1998) (95)
Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. (2013) (92)
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies (2016) (92)
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease (2000) (90)
Potentiation of human erythropoiesis in vitro by thyroid hormone (1978) (88)
Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. (1996) (88)
Somatic mutations and cell identity linked by Genotyping of Transcriptomes (2019) (87)
Ex vivo expansion of autologous bone marrow CD34(+) cells with porcine microvascular endothelial cells results in a graft capable of rescuing lethally irradiated baboons. (1999) (86)
Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. (1996) (86)
An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. (1985) (85)
Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. (2005) (84)
Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies. (1982) (84)
Apoptosis of human hematopoietic progenitor cells induced by crosslinking of surface CD43, the major sialoglycoprotein of leukocytes. (1995) (81)
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. (2009) (81)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis (2017) (80)
The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells. (1997) (80)
Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines. (1995) (80)
Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. (2012) (77)
Granulocyte colony-stimulating factor induction of normal human bone marrow progenitors results in neutrophil-specific gene expression. (1995) (77)
Basic fibroblast growth factor promotes the proliferation of human megakaryocyte progenitor cells. (1993) (76)
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post‐polycythaemia vera/essential thrombocythaemia myelofibrosis (post‐PV/ET MF) (2013) (76)
Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. (1993) (75)
Purification and partial characterization of a megakaryocyte colony-stimulating factor from human plasma. (1985) (75)
Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. (1994) (75)
In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. (1993) (74)
Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. (1997) (73)
Cytokine regulation of the human burst-forming unit-megakaryocyte. (1990) (72)
Bone marrow repopulation by human marrow stem cells after long-term expansion culture on a porcine endothelial cell line. (1998) (72)
What are RBC-transfusion-dependence and -independence? (2011) (72)
Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. (2010) (69)
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (2008) (69)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. (2013) (69)
Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells (1988) (68)
Mechanisms of abnormal erythropoiesis in malignancy (1983) (68)
CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. (1999) (67)
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. (2014) (66)
Therapeutic options for patients with myelofibrosis in blast phase. (2010) (66)
Further examination of the effects of recombinant cytokines on the proliferation of human megakaryocyte progenitor cells. (1991) (65)
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. (2007) (64)
Oral Idasanutlin in Patients with Polycythemia Vera. (2019) (63)
Transmission of idiopathic (autoimmune) thrombocytopenic purpura by liver transplantation. (1990) (63)
Leukemia inhibitory factor upregulates cytokine expression by a murine stromal cell line enabling the maintenance of highly enriched competitive repopulating stem cells. (1996) (63)
The in vitro and in vivo effects of stem cell factor on human hematopoiesis (1993) (61)
Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft. (1995) (61)
Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. (1993) (61)
Identification of CD34+ subsets after glycoprotease selection: engraftment of CD34+Thy-1+Lin- stem cells in fetal sheep. (1996) (61)
Studies of the route of administration and role of conditioning with radiation on unrelated allogeneic mismatched mesenchymal stem cell engraftment in a nonhuman primate model. (2004) (61)
Genotyping of Transcriptomes links somatic mutations and cell identity (2019) (61)
The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. (2014) (61)
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. (2007) (61)
Dysregulated iron metabolism in polycythemia vera: etiology and consequences (2018) (60)
White blood cells 1: non-malignant disorders (2000) (60)
Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation (2008) (60)
A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells. (1996) (59)
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. (2005) (59)
Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. (2015) (58)
Induction of erythropoietic colonies in a human chronic myelogenous leukemia cell line. (1979) (58)
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. (2019) (57)
CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. (1999) (57)
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. (2015) (56)
Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells. (1996) (56)
Constitutive expression of platelet glycoproteins by the human leukemia cell line K562 (1982) (55)
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. (2008) (54)
Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor. (1989) (54)
Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. (2012) (53)
Mitochondrial Role in Stemness and Differentiation of Hematopoietic Stem Cells (2019) (53)
In vitro studies of megakaryocytopoiesis in thrombocytotic disorders of man. (1983) (53)
Temporal adaptation of neutrophil oxidative responsiveness to n-formyl-methionyl-leucyl-phenylalanine. Acceleration by granulocyte-macrophage colony stimulating factor. (1988) (53)
Cytokines for the treatment of thrombocytopenia. (2007) (53)
Wheezing and asthma are independent risk factors for increased sickle cell disease morbidity (2012) (52)
Role of cytokines in sustaining long-term human megakaryocytopoiesis in vitro. (1992) (52)
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. (2007) (51)
Establishment in long term culture of megakaryocytic leukemia cells (EST-IU) from the marrow of a patient with leukemia and a mediastinal germ cell neoplasm. (1986) (51)
A trial of recombinant α2 interferon in the myelodysplastic syndromes: I. Clinical results (1987) (51)
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. (2012) (50)
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents (2006) (50)
The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. (2011) (49)
Regulation of human megakaryocytopoiesis. An in vito analysis. (1981) (48)
Simultaneous use of rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells. (1991) (48)
Cyclic thrombocytopenia of apparent autoimmune etiology. (1989) (47)
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. (2018) (47)
Anti-transforming growth factor-β therapy in patients with myelofibrosis (2014) (47)
Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. (1996) (47)
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. (1996) (46)
Biology and treatment of primary myelofibrosis. (2007) (46)
Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD/SCID mice. (2007) (46)
Regimen-related toxicity after fludarabine–melphalan conditioning: a prospective study of 31 patients with hematologic malignancies (2003) (46)
Defective expression of the SHP-1 phosphatase in polycythemia vera. (1999) (46)
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. (2012) (46)
An Open-Label Study of CEP-701 in Patients with JAK2 V617F-Positive PV and ET: Update of 39 Enrolled Patients. (2009) (45)
Cyclic thrombocytopenia of apparent autoimmune etiology (1989) (45)
The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. (1998) (45)
Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. (1996) (44)
Endothelial Precursor Cells in the Peripheral Blood of Pregnant Women (2002) (44)
Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts. (1994) (43)
Relationship between cytokine-dependent cell cycle progression and MHC class II antigen expression by human CD34+ HLA-DR- bone marrow cells. (1992) (43)
Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells. (1995) (42)
Effect of perturbation of specific folate receptors during in vitro erythropoiesis. (1987) (42)
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl (2016) (42)
Hemin control of heme biosynthesis and catabolism in a human leukemia cell line (1980) (42)
KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. (1988) (42)
MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis (2019) (42)
Autoimmune hemolytic anemia and periodic pure red cell aplasia in systemic lupus erythematosus. (1978) (41)
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production. (2000) (41)
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET) (2018) (41)
Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. (1996) (40)
Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. (2007) (40)
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. (2018) (39)
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. (2020) (39)
Isolation of human megakaryocytes by density centrifugation and counterflow centrigual elutriation. (1984) (39)
Evidence for the clonal nature of hypereosinophilic syndrome. (1988) (39)
Retention of long-term repopulating ability of xenogeneic transplanted purified adult human bone marrow hematopoietic stem cells in sheep. (1995) (39)
Translational Approaches in Tissue Engineering and Regenerative Medicine (2008) (38)
Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia (2016) (38)
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. (2019) (38)
ANALYSIS OF PHORBOL ESTER STIMULATED HUMAN MEGAKARYOCYTE DEVELOPMENT (1988) (38)
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. (2009) (38)
Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels (2018) (38)
Erythropoietin-dependent primary pure erythrocytosis. (1979) (38)
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. (2019) (37)
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies (2011) (37)
PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks (2015) (37)
Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results (2014) (37)
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. (2016) (36)
Progress in the development of systems for in vitro expansion of human hematopoietic stem cells. (1999) (35)
Isoniazid-induced pure red cell aplasia. (1983) (35)
Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis. (1998) (35)
Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. (2017) (35)
Humoral suppression of erythropoiesis in systemic lupus erythematosus (SLE) and rheumatoid arthritis. (1980) (34)
Management of the myelodysplastic syndromes. (1987) (34)
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. (2001) (34)
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. (2020) (34)
A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC). (2009) (34)
Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. (2018) (34)
Constitutive expression of platelet glycoproteins by the human leukemia cell line K562. (1982) (34)
The influence of T lymphocyte subsets and humoral factors on colony formation by human bone marrow and blood megakaryocyte progenitor cells in vitro. (1986) (33)
Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia. (2014) (33)
Human megakaryocyte production: cell biology and clinical considerations. (1990) (33)
Highly abundant genes in the transcriptosome of human and baboon CD34 antigen-positive bone marrow cells. (2001) (33)
Acquired pure amegakaryocytic thrombocytopenic purpura. (1991) (32)
Ex vivo human HSC expansion requires coordination of cellular reprogramming with mitochondrial remodeling and p53 activation. (2018) (32)
Is interleukin 6 the physiological regulator of thrombopoiesis? (1992) (32)
An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells (2000) (32)
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis (2021) (32)
Human umbilical cord blood hematopoietic progenitor cells: are they the same as their adult bone marrow counterparts? (1994) (32)
Lymphoblastic-like leukemic transformation of polycythemia vera. (1978) (32)
Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis (2017) (31)
Clinical Insights into the Origins of Thrombosis in Myeloproliferative Neoplasms. (2020) (31)
Cocultivation of umbilical cord blood cells with endothelial cells leads to extensive amplification of competent CD34+CD38- cells. (2000) (31)
BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. (2013) (31)
Terminal cytoplasmic maturation of human megakaryocytes in vitro. (1986) (30)
Recombinant GM-CSF/IL-3 fusion protein: its effect on in vitro human megakaryocytopoiesis. (1992) (30)
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis. (2012) (30)
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. (2010) (30)
New insights into the regulation of human megakaryocytopoiesis. (1987) (29)
Human CD34+ cells are capable of generating normal and JAK2V617F positive endothelial like cells in vivo. (2009) (28)
Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. (2006) (28)
Enriched hematopoietic stem cells: basic biology and clinical utility. (1995) (28)
Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials (2014) (28)
Open‐label study of oral CEP‐701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2‐V617F mutation (2014) (27)
Clinical and laboratory features of myelofibrosis and limitations of current therapies. (2011) (27)
High-level expression of a novel epitope of CD59 identifies a subset of CD34+ bone marrow cells highly enriched for pluripotent stem cells. (1996) (27)
Blastic transformation of essential thrombocythemia: dual expression of myelomonoblastic/megakaryoblastic phenotypes. (1984) (27)
Differing responses of globin and glycophorin gene expression to hemin in the human leukemia cell line K562. (1982) (27)
In vitro correction of anticoagulant activity and specific clotting factor assays in SLE. (1980) (26)
Long-term hematopoietic culture-initiating cells are more abundant in mobilized peripheral blood grafts than in bone marrow but have a more limited ex vivo expansion potential. (1996) (26)
Clinical pharmacokinetic study of tiazofurin administered as a 1‐hour infusion (1992) (26)
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. (2015) (25)
Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia (1993) (25)
Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. (2018) (25)
Chromatin-modifying agents promote the ex vivo production of functional human erythroid progenitor cells. (2010) (25)
A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF). (2009) (25)
Transitory hypomegakaryocytic thrombocytopenia: aetiological association with ethanol abuse and implications regarding regulation of human megakaryocytopoiesis (1986) (24)
A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). (2017) (24)
Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis (2014) (24)
Retroviral-mediated gene transfer of bone marrow cells during autologous bone marrow transplantation for acute leukemia. (1992) (24)
Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. (2005) (24)
Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. (2010) (24)
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis (2015) (24)
Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. (2011) (24)
Human megakaryocyte progenitor cells. (1998) (24)
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. (2015) (24)
Involvement of various hematopoietic-cell lineages by the JAK 2 V 617 F mutation in polycythemia (2006) (23)
Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition (2012) (23)
Effects of megakaryocyte colony-stimulating factor on terminal cytoplasmic maturation of human megakaryocytes. (1987) (23)
Megaloblastic hematopoiesis in vitro. Interaction of anti-folate receptor antibodies with hematopoietic progenitor cells leads to a proliferative response independent of megaloblastic changes. (1991) (23)
Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. (2004) (23)
Mutant H-ras over-expression inhibits a random apoptotic nuclease in myeloid leukemia cells. (1993) (23)
An in vivo competitive repopulation assay for various sources of human hematopoietic stem cells. (2000) (22)
Primate skeletal muscle contains cells capable of sustaining in vitro hematopoiesis. (2002) (22)
Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation (2006) (22)
Natural history and management of polycythemia vera. (1979) (22)
Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. (1993) (21)
In vitro steroid sensitivity testing: A possible means to predict response to therapy in primary hypoproliferative anemia (1980) (21)
Detection of human cells in human/sheep chimeric lambs with in vitro human stroma-forming potential. (1996) (21)
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia (2022) (21)
Hemin control of heme biosynthesis and catabolism in a human leukemia cell line. (1980) (21)
Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients (2019) (21)
Ex vivo HSC expansion challenges the paradigm of unidirectional human hematopoiesis (2019) (21)
Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia * (2010) (21)
Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein. (1989) (21)
A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). (2019) (20)
Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-α 2a in a patient with polycythemia vera (2007) (20)
LKB1/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms. (2021) (20)
Phase I/II study of single‐agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition (2010) (19)
Association of 5q− and refractory anemia (1978) (19)
Use of Molecular Testing to Identify a Cluster of Patients with Polycythemia Vera in Eastern Pennsylvania (2009) (19)
Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma (2006) (19)
Why does my patient have erythrocytosis? (2012) (19)
TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis (2021) (19)
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis (2019) (19)
Fetal hemoglobin in polycythemia vera: cellular distribution in 50 unselected patients. (1979) (18)
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. (2016) (18)
PE-1, a novel ETS oncogene family member, localizes to chromosome 1q21-q23. (1994) (18)
Detection of a primitive megakaryocyte progenitor cell in human fetal bone marrow. (1996) (18)
Allogeneic T cells induce rapid CD34+ cell differentiation into CD11c+CD86+ cells with direct and indirect antigen-presenting function. (2006) (17)
Chronic T cell lymphoproliferative disorder and pure red cell aplasia. Further characterization of cell-mediated inhibition of erythropoiesis and clinical response to cytotoxic chemotherapy. (1987) (17)
AVID200, a Potent Trap for TGF-β Ligands Inhibits TGF-β1 Signaling in Human Myelofibrosis (2018) (17)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis. (2016) (17)
An acute myeloproliferative disorder characterized by myelofibrosis and blast cells that express phenotypic properties associated with multiple hematopoietic lineages. (1985) (17)
Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis (2011) (17)
Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor (2020) (16)
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial (2016) (16)
Sensitive detection of MPLW515L/K mutations by amplification refractory mutation system (ARMS)-PCR. (2010) (16)
Chloride transport properties of human leukemic cell lines K562 and HL60. (1984) (16)
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis (2019) (16)
Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms. (2016) (16)
Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia (2017) (16)
Advances in myelofibrosis: a clinical case approach (2013) (16)
Pulmonary extramedullary hematopoiesis in patients with myelofibrosis undergoing allogeneic stem cell transplantation (2008) (15)
CD34+Thy-1+Lin- stem cells from mobilized peripheral blood. (1996) (15)
Regulation of heme metabolism in normal and sideroblastic bone marrow cells in culture. (1985) (15)
Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. (2009) (15)
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms (2009) (15)
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial) (2016) (15)
Hierarchical Structure of Human Megakaryocyte Progenitor Cells (1996) (14)
Ex vivo expansion of hematopoietic stem cells: Finally transitioning from the lab to the clinic. (2021) (14)
Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis (2007) (14)
New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches (2019) (14)
Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders. (2008) (13)
A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results. (1987) (13)
Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates. (2004) (13)
Idiopathic myelofibrosis. (2005) (13)
A Multidisciplinary Investigation of a Polycythemia Vera Cancer Cluster of Unknown Origin (2010) (13)
Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis (2011) (12)
Studies of human megakaryocytopoiesis using an anti-megakaryocyte colony-stimulating factor antiserum. (1986) (12)
Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. (2020) (12)
Current considerations of the etiology of aplastic anemia. (1985) (12)
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis (2019) (12)
Primitive human hematopoietic progenitor cells express receptors for granulocyte-macrophage colony-stimulating factor. (1999) (12)
Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis (2015) (12)
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial (2013) (12)
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms (2019) (12)
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results. (2014) (12)
The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. (2018) (12)
Characterization Of Splenic Fibroblasts From Patients With Myelofibrosis (2013) (11)
Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms (2020) (11)
Antibody-mediated acquired sideroblastic anemia: response to cytotoxic therapy. (1979) (11)
T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation (2007) (11)
Feline Preleukemia: An Animal Model of Human Disease 1 (1978) (11)
Inosine monophosphate dehydrogenase inhibitors. Probes for investigations of the functions of guanine nucleotide binding proteins in intact cells. (1990) (11)
Animal models for human hematopoiesis. (1992) (11)
Continued Role of Splenectomy in the Management of Patients With Myelofibrosis. (2016) (11)
All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. (2000) (11)
A Phase 2 Study of Cpi-0610, a Bromodomain and Extraterminal (BET) Inhibitor, in Patients with Myelofibrosis (MF) (2018) (10)
The Smad 5 Gene Is Involved in the Intracellular Signaling Pathways That Mediate the Inhibitory Effects of Transforming Growth Factor-b on Human Hematopoiesis (1998) (10)
Measurement of marrow repopulating potential of human hematopoietic progenitor and stem cells using a fetal sheep model. (1994) (10)
Sideroblastic anemia: Differences in bone marrow erythroid colony (CFUe) growth responses to erythropoietin in plasma clot and methylcellulose cultures (1984) (10)
Safety and outcome after fludarabine–thiotepa–TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies (2003) (10)
Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. (2011) (10)
Modern management of splenomegaly in patients with myelofibrosis (2020) (10)
Pre‐clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice (2019) (10)
The proliferative capacity of pure red cell aplasia bone marrow cells. (1981) (10)
PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients (2020) (10)
Serum from patients with various thrombopoietic disorders alters terminal cytoplasmic maturation of human megakaryocytes in vitro (1989) (10)
Associations of Physical and Psychologic Symptom Burden in Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. (2018) (10)
Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience (2019) (10)
Role of epigenetic reprogramming in hematopoietic stem cell function (2015) (10)
Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms. (2016) (10)
Imbalanced globin chain synthesis in cultured erythroid progenitor cells from thalassemic bone marrow and peripheral blood. (1981) (10)
Effects of thrombocytopoiesis-stimulating factor on terminal cytoplasmic maturation of human megakaryocytes. (1989) (9)
Retroviral mediated gene transfer in chronic myelogenous leukaemia (1994) (9)
Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome. (2011) (9)
Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial (2020) (9)
An Open-Label, Phase II Study Of The JAK1 Inhibitor INCB039110 In Patients With Myelofibrosis (2013) (9)
Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients (2020) (9)
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? (2015) (9)
High throughput droplet single-cell Genotyping of Transcriptomes (GoT) reveals the cell identity dependency of the impact of somatic mutations (2018) (9)
Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications. (2021) (9)
Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis (2014) (9)
Ex vivo expansion of CD34+ cells from purified adult human bone marrow and umbilical cord blood hematopoietic progenitor cells. (1994) (8)
Ex Vivo Expansion and Genetic Marking of Primitive Human and Baboon Hematopoietic Cells (1999) (8)
Quality of life issues in patients with essential thrombocythemia and polycythemia vera. (2002) (8)
The Role of Other Hemopoietic Growth Factors and the Marrow Microenvironment in Megakaryocytopoiesis (1997) (8)
Evidence for organ‐specific stem cell microenvironments (2010) (8)
Hemichorea in a patient with JAK2V617F blood cells. (2013) (8)
Characterization of primitive marrow CD34+ cells that persist after a sublethal dose of total body irradiation. (2005) (8)
Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Pha (2017) (8)
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid. (2019) (7)
Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production (2021) (7)
Rusfertide (PTG-300) Induction Therapy Rapidly Achieves Hematocrit Control in Polycythemia Vera Patients without the Need for Therapeutic Phlebotomy (2021) (7)
In vivo effects of recombinant human stem cell factor treatment. A morphologic and immunohistochemical study of bone marrow biopsies. (1995) (7)
Primitive hematopoietic progenitor cells are present in peripheral blood autografts. (1994) (7)
Therapy for the Treatment of Myelofibrosis (2012) (7)
Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial) (2018) (7)
Myeloproliferative neoplasms: new translational therapies. (2010) (7)
p53 as a target in myeloproliferative neoplasms (2012) (7)
Genomic characterization of spleens in patients with myelofibrosis (2018) (7)
Cytogenetic findings in siblings with a myelodysplastic syndrome. (1987) (7)
Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders. (2017) (7)
A variant t(X;15)(p11;q22) translocation in acute promyelocytic leukemia. (1987) (7)
Clarifying the use of ruxolitinib in patients with myelofibrosis. (2013) (7)
Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. (2017) (7)
Current approaches to challenging scenarios in myeloproliferative neoplasms (2018) (6)
Pleckstrin-2 is essential for erythropoiesis in β-thalassemic mice, reducing apoptosis and enhancing enucleation (2021) (6)
Preferences of Patients With Myeloproliferative Neoplasms for Accepting Anxiety or Depression Treatment. (2017) (6)
Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia (2020) (6)
The presence of JAK 2 V 617 F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome (2009) (6)
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (2021) (6)
RBC-transfusion guidelines update. (2012) (6)
Definition of Early Progenitors and Functional Maturation of Human Natural Killer Cells: Requirements for Cytocidal Activity (1998) (6)
Effects of recombinant human tumor necrosis factor alpha, recombinant human gamma-interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin alpha, and recombinant erythropoietin in serum (1986) (6)
Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells (2020) (6)
Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia. (2019) (6)
Numerous growth factors can influence in vitro megakaryocytopoiesis. (1990) (5)
Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders Research Consortium (MPD-RC) (2016) (5)
A phase II study of cpi-0610, a bromodomain and extraterminal protein inhibitor (BETi) alone or with ruxolitinib (RUX), in patients with myelofibrosis (MF). (2019) (5)
Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia (2021) (5)
Control of thrombocytopoiesis: current state of the art. (1995) (5)
Stem cell transplantation : biology, processing, and therapy (2006) (5)
Ex Vivo Expansion of Adult Hematopoietic Stem and Progenitor Cells with Valproic Acid. (2021) (5)
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera (2015) (5)
Allogeneic hsct with reduced intensity conditioning regimens in high risk patients with myelofibrosis (2004) (5)
Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms (2017) (5)
Variable in vitro erythropoiesis in patients with transient erythroblastopenia of childhood. (1985) (5)
An Association of Myeloproliferative Neoplasms and Obliterative Portal Venopathy (2014) (5)
Is bone marrow fibrosis the real problem (2006) (5)
Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia (2014) (4)
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms (2022) (4)
Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF. (1997) (4)
Evaluation of a clinical-grade, cryopreserved, ex vivo-expanded stem cell product from cryopreserved primary umbilical cord blood demonstrates multilineage hematopoietic engraftment in mouse xenografts. (2021) (4)
Alteration of Hematopoietic Stem Cell Fates by Chromatin‐Modifying Agents (2006) (4)
Characterization of human hematopoietic stem cells. (1990) (4)
Feline preleukemia: an animal model of human disease. 1978. (2000) (4)
Psychological Manifestations of Early Childhood Adversity in the Context of Chronic Hematologic Malignancy. (2017) (4)
A Single-Cell Approach to Unraveling Abnormal Megakaryocyte Differentiation and Function in Myelofibrosis (2017) (4)
Bone marrow CD34+ cells expanded on human brain endothelial cells reconstitute lethally irradiated baboons in a variable manner (2010) (4)
Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While Controlling Hematocrit in Polycythemia Vera Patients (2020) (4)
An Outline of the Outset of Thrombopoiesis in Human Embryos At Last. (2021) (4)
The possible role of mutated endothelial cells in myeloproliferative neoplasms (2021) (4)
Interleukin 10‐induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production (2000) (4)
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings (2019) (4)
The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib (2019) (4)
First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. (2010) (4)
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition (2022) (4)
Effects of adherent bone marrow stromal cells on the development and proliferation of highly purified human hematopoietic stem cells. (1992) (3)
Cytokine control of human megakaryocytopoiesis. (1990) (3)
Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN) (2014) (3)
Human Hematopoietic Stem Cells: Potential Use as Tumor‐Free Autografts After High‐Dose Myeloablative Cancer Therapy (1995) (3)
Landscape of TP53 Mutations in MPN (2019) (3)
Preleukemic state preceding adult acute lymphoblastic leukemia. (1990) (3)
Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells (2019) (3)
Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy (2022) (3)
Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms (2020) (3)
Whirling Platelets Away for Transfusion (2018) (3)
Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies (2016) (3)
Characterization of Splenic CD34+ Cells From Patients with Primary Myelofibrosis (2011) (3)
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database (2019) (3)
Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow. (1992) (3)
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials (2021) (3)
Combination Treatment with an MDM2 Antagonist and a BET Inhibitor Targets Both Myelofibrosis Hematopoietic Stem/ Progenitor Cells and Their Tumor Promoting Microenvironment (2017) (3)
Modeling Calreticulin-Mutant Myeloproliferative Neoplasms with Isogenic Induced Pluripotent Stem Cells (2018) (3)
Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms (2020) (3)
HMGA2, a Member of the High Mobility Group Gene Family, Is Expressed at the Protein Level in Peripheral Blood CD34+ Cells of Patients with Idiopathic Myelofibrosis and Polycythemia Vera. (2004) (3)
Hematopoietic stem cell behavior: potential implications for gene therapy. (1995) (3)
Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis (2014) (3)
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms (2010) (3)
Drosophila Forkhead homologues are expressed in CD34+/HLA-DR- primitive human hematopoietic progenitors. (1994) (3)
Splenic Micro Environmental Cells from Patients with Myelofibrosis Elaborate a Cascade of Cytokines and Serve As a Niche for Malignant Hematopoiesis (2016) (3)
Influence of T lymphocytes on hematopoiesis in a patient with T cell hypoplasia (1988) (3)
Navtemadlin (KRT-232), a Small Molecule MDM2 Inhibitor, Is More Effective Than Decitabine Against Myeloproliferative Neoplasm-Blast Phase in a Patient-Derived Xenograft Model (2021) (3)
Detection of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. (1988) (2)
European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database (2021) (2)
Integrated Single-Cell Genotyping and Chromatin Accessibility Charts JAK2V617F Human Hematopoietic Differentiation (2022) (2)
Chapter 68 – The Polycythemias (2018) (2)
Panobinostat (LBH589)-Mediated Acetylation of Tubulin Plays a Role in Megakaryocyte Maturation and Platelet Release (2011) (2)
IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. (2022) (2)
Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study (2020) (2)
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase (2022) (2)
Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019 (2020) (2)
Evidence for an Environmental Influence Leading to the Development of JAK2 V617F-Positive Polycythemia Vera: A Molecular Epidemiological Study. (2007) (2)
JAK inhibitors in the treatment of myelofibrosis. (2022) (2)
What are the molecular mechanisms driving the switch from MPNs to leukemia? (2021) (2)
A Novel Combination of Drugs Which Target Both the Intrinsic and Extrinsic Apoptotic Pathways to Eliminate Myelofibrosis CD34+ Cells (2019) (2)
In vitro hematopoiesis following induction chemotherapy for acute leukemia. (1985) (2)
Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119 (2022) (2)
Treatment in Vitro with a Combination of Bcl-Xl Inhibitor-ABT-737 and a JAK2 Inhibitor Selectively Eliminates JAK2V617F MPN Progenitor Cells. (2009) (2)
Biological drivers of clinical phenotype in myelofibrosis (2022) (2)
A Phase I Study of the Proteasome Inhibitor Bortezomib in Patients with Myelofibrosis. (2007) (2)
Ex Vivo Expansion of Human Hematopoietic Stem Cells: Implications for The Modern Blood Bank (1998) (2)
Don't judge a JAK2 inhibitor by spleen response alone. (2017) (2)
Reduced Expression of CXCR4 on Circulating CD34+ Cells Is Associated with Hematopoietic Progenitor Cells (HPC) Mobilization in Patients with Myelofibrosis with Myeloid Metaplasia (MMM). (2005) (2)
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis (2022) (2)
Separate factors control terminal cytoplasmic maturation of human megakaryocytes. (1986) (2)
Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin Modifying Agents (2008) (2)
Advanced Forms of the Myeloproliferative Neoplasms Are Associated with Chromosomal Abnormalities Involving 1q and 12q: Implicating MDM2 and MDM4 in Disease Progression (2017) (2)
An MDM2 degrader for treatment of acute leukemias (2021) (2)
Tumor Contamination , and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma (1998) (2)
Preclinical Development of a Cryopreservable Megakaryocyte Cell Product from Cord Blood Derived Hematopoietic Stem Cells (2016) (1)
Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients. (2004) (1)
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. (2021) (1)
Aberrant Responsiveness of Erythropoiesis to Iron Deficiency in Polycythemia Vera (2019) (1)
Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia? (2019) (1)
Bone Marrow Microenvironment in Health and Disease (2020) (1)
Novel treatments to tackle myelofibrosis (2018) (1)
Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics (2021) (1)
Outcomes in Myelofibrosis Patients Completing 24 and 36 Weeks of Treatment with PRM-151 (2015) (1)
Studies of BFU-E in Flask Cultures of Human Peripheral and Cord Blood Cells 1 (1983) (1)
Outcomes of Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms Treated with Direct Oral Anticoagulants (2019) (1)
MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study (2021) (1)
Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms (2019) (1)
Real-World Outcomes of Ruxolitinib for Polycythemia Vera (2017) (1)
The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells (2019) (1)
Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis (2006) (1)
AP-1/C-jun and C-myc Regulation During Megakaryocytic Differentiation of a Human Bi-potential Growth-factor-dependent Cell Line. (1995) (1)
Treatment with Pegylated Interferon Alpha 2a in Combination with the Bcl-Xl Inhibitor ABT-737 Specifically Targets JAK2V617F Positive Hematopoietic Progenitor Cells From Patients with Polycythemia Vera. (2009) (1)
Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy (2020) (1)
LONG-TERM MULTILINEAGE DEVELOPMENT FROM HUMAN UMBILICAL CORD BLOOD STEM CELLS IN A NOVEL SCID-HU GRAFT (1996) (1)
Mast Cells Are Involved by the Malignant Process and Play An Important Role in the Pruritogenesis in Patients with Myeloproliferative Disorders (2008) (1)
The role of purified and recombinant hematopoietic growth factors in the regulation of various stages of human megakaryocytopoiesis. (1988) (1)
Use of Pegylated Interferon in Six Pediatric Patients with Myeloproliferative Neoplasms (2019) (1)
HEMATOPOIESIS Ex Vivo Expansion of Autologous Bone Marrow CD 34 1 Cells With Porcine Microvascular Endothelial Cells Results in a Graft Capable of Rescuing Lethally Irradiated Baboons (1999) (1)
Recent advances in prognostication and treatment of polycythemia vera (2021) (1)
Histone Deacetylase Inhibitors Promote the Ex Vivo Expansion of Cord Blood CD34+ Cells in Serum Free Cultures Accompanied by the Upregulation of Pluripotency Genes (2012) (1)
Erythropoiesis during an erythroblastic transformation of chronic myelocytic leukemia (1981) (1)
Thrombopoietin Affects the Behavior of Myelofibrosis Stem Cells (2014) (1)
Rational therapeutic options for patients with myeloproliferative neoplasms. (2011) (1)
An Inhibitor of TGF-β Promotes Proliferation of Normal but Not MPN Hematopoietic Cells and Is a Candidate Therapeutic Agent for the Treatment of MPN Patients Carrying JAK2 V617F or Calr pQ365fs Mutations (2015) (1)
The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 low Mice (2022) (1)
S831 CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS (2019) (1)
Special Issue on Stem Cell Plasticity (2002) (1)
High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations (2018) (1)
Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells (2021) (1)
Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin (2019) (1)
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis (2021) (1)
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myeloﬁbrosis with myeloid metaplasia (2005) (1)
Targeting Non-Histone Protein Acetylation Impairs Platelet Production During Normal Megakaryocytopoiesis. (2010) (1)
Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (2016) (1)
Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias (2008) (1)
Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias (2008) (1)
Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Hematopoietic Stem Cells (2018) (1)
Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial. (2004) (1)
Inversion of Chromosome 12 and Translocations of 12q13-q15 In Primary Myelofibrosis (PMF) Are Associated with Disease Progression and a Poor Prognosis (2010) (1)
Disruption of MDM2-p53 Interactions by a Small Molecule Inhibitor RG7112 Increases Apoptosis and Impairs Polyploidization of Human Megakaryocytes (2012) (1)
Bone marrow transplantation: from last resort to preferred therapy. (1985) (1)
Epigenetic Regulation of Normal Hematopoietic Development (2014) (1)
32-MPN and Plasma Dyscrasia Monoclonal Gammopathy of Undetermined Signi fi cance (1)
Imetelstat, a Telomerase Inhibitor, Is Capable of Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells (2017) (1)
Humoral regulation of human megakaryocytopoiesis. (1985) (0)
Sequential Treatment of CD34+ Cells From Patients with Primary Myelofibrosis with Chromatin Modifying Agents Alters the Behavior of JAK2V617F Positive NOD/SCID Marrow Repopulating Cells. (2009) (0)
Verify: A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (2022) (0)
Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis (2019) (0)
Bone Marrow CD34+ Cells Expanded On Human Brain Endothelial Cells Reconstitutes Lethally Irradiated Baboons in a Variable Manner. (2009) (0)
Potent In Vitro Peptide Antagonists of the Thrombopoietin Receptor as Potential Myelofibrosis Drugs (2021) (0)
Non-Human Primate Models of Mesenchymal Stem Cell Transplantation (2006) (0)
Digital Immune Expression Profiling Coupled with Immunohistochemistry for Interrogation of Microenvironment in Formalin Fixed Paraffin Embedded Specimens of Marrow and Spleen from PMF Patients (2015) (0)
Treatment of congenital bone marrow failure with cytokines (1992) (0)
Two Classes of Progenitor Cells in Patients with Myeloproliferative Disorders Are Capable of Generating JAK2V617F+CD31+CD144+ Endothelial Cells. (2007) (0)
303: Role of Extensive Splenomegaly in Patients with Myelofibrosis undergoing a Reduced Intensity Allogeneic Stem Cell Transplant (2008) (0)
A tribute to Alan M. Gewirtz: September 3, 1949−November 17, 2010 (2011) (0)
Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis (2022) (0)
High Throughput Single-Cell Simultaneous Genotyping and Chromatin Accessibility Reveals Genotype to Phenotype Relationship in Human Myeloproliferation (2021) (0)
for myelofibrosis research and treatment (IWG-MRT) response in myelofibrosis with myeloid metaplasia: On behalf of the IWG International Working Group (IWG) consensus criteria for treatment (2013) (0)
MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study (2021) (0)
Human CD341 stem cells express theiwi gene, a human homologue of theDrosophilagenepiwi (2001) (0)
Survey and evaluation of mutations in the human KLF1 transcription unit (2018) (0)
Searching for polycythemia vera's Holy Grail (2006) (0)
A thrombopoietin antagonist is capable of affecting stem and progenitor cells of patients with myelofibrosis (2014) (0)
Use of Chromatin Modifying Agents for Ex Vivo Expansion of Human Umbilical Cord Blood Stem Cells. (2005) (0)
Abstract LB-54: Interferon targets JAK2V617F positive hematopoietic progenitor cells and acts through the p38 MAP kinase pathway (2010) (0)
Prevalence Of The JAK2V617F Mutation and Associated Risk Haplotype and Determination Of Demographic and Lifestyle Risk Factors In The US Population, Nhanes 1999-2002 (2013) (0)
Nonhuman Primate Models of Hematopoietic Stem Cell Transplantation (2003) (0)
609 LOCALIZATION OF THE SITE OF ACTION OF A SERUM INHIBITOR OF ERYTHROPOIESIS (1978) (0)
Preclinical Advances in the Pathogenesis and Therapy of Myeloproliferative Neoplasms TET 2 (2012) (0)
Engraftment of Subpopulations of Hematopoietic Cells from Patients with Polycythemia Vera in NOD/SCID Mice. (2006) (0)
Faculty Opinions recommendation of Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. (2021) (0)
Isoniazid‐lnduced Pure Red Cell Aplasia (1983) (0)
Expansion and Clinical use of Hematopoietic Progenitor Cells in Human Marrow and Peripheral Blood (2020) (0)
The Relationship Between Chromosomally Abnormal Hematopoiesis and the JAK2V617F Allele Burden in Patients (pts) with Ph-Negative Chronic Myeloproliferative Disorders (Ph-neg MPD) (2008) (0)
Subgroup Analysis of Adverse Events Following Rusfertide Dosing in Revive: A Phase 2 Study of Patients with Polycythemia Vera (2022) (0)
Human megakaryocytopoiesis. (1986) (0)
Transcriptional Characterization of Myelofibrotic Bone Marrow Microenvironment Reveals Distinct Tumor Microenvironment in JAK2+ and Calr+ PMF Marrows (2016) (0)
Characterization of the Hematopoietic Stem Cell in the Peripheral Blood of Patients with Idiopathic Myelofirosis (2008) (0)
The Effects of Lipocalin (LCN2) on Hematopoiesis in Primary Myelofibrosis (2014) (0)
Interferon α Has Varied Effects On CD34+ Cells From Patients With Polycythemia Vera (2013) (0)
international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis (2020) (0)
Shared and Tissue-Specific Genetic Features of Primary Myelofibrosis, Hepatic Fibrosis, Idiopathic Pulmonary Fibrosis and Kidney Fibrosis (2017) (0)
Effects of Recombinant Human Tumor Necrosis Factor a, Recombinant Human 7-Interferon, and Prostaglandin E on Colony Formation of Human Hematopoietic Progenitor Cells Stimulated by Natural Human Pluripotent Colonystimulating Factor, Pluripoietin a, and Recombinant Erythropoietin in Serum-free Culture (2006) (0)
Specific and Recurrent Cytogenomic Abnormalities Originate in the Spleens of Myelofibrosis Patients and Contribute to Clonal Diversity and Disease Progression (2014) (0)
Characterization and Isolation of Splenic Littoral Cells, a Possible Cellular Niche for Extramedullary Hematopoiesis in Myelofibrosis (2015) (0)
Introduction: The seed was planted in Experimental Hematology (2007) (0)
Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis (2022) (0)
The Effect of JAK 1/2 Inhibitors on Outcomes of Allogeneic Stem Cell Transplantation for Patients with Myelofibrosis (2018) (0)
Isolation of Both Normal and Leukemic Cells Within the Hematopoietic Stem Cell Compartment of Chronic Myelogenous Leukemia Mobilized Peripheral Blood (2020) (0)
Human hematopoietic stem cells: Characterization and potential clinical use (1994) (0)
Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment (2022) (0)
expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
The effect of in vivo administration of recombinant methionyl human stem cell factor on the number of human marrow hematopoietic stem cells. (1993) (0)
progenitor cells Role of c-kit ligand in the expansion of human hematopoietic (2011) (0)
Environmental Toxins Found Historically in the Polycythemia Vera Cluster Area and their Potential for Inducing DNA Damage (2021) (0)
Outcomes of Abdominal Thrombosis in Patients with Myeloproliferative Neoplasms in a Single Center Experience (2018) (0)
Stromal Cells-Mediated Inhibition of Erythropoiesis Can Be Counteracted by Sotatercept (ACE-011), an Activin Receptor Type II (ActRIIA) Fusion Protein (2012) (0)
Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML). (2009) (0)
The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells (2015) (0)
Recurrent Amplified Regions on the Long Arm of Chromosome 1 (1q) Are Associated with Disease Progression In Ph-Negative Myeloproliferative Neoplasms (MPN) (2010) (0)
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. (2023) (0)
expression bone marrow progenitors results in neutrophil-specific gene Granulocyte colony-stimulating factor induction of normal human (2011) (0)
Somatic mutations and cell identity linked by Genotyping of Transcriptomes (2019) (0)
The Thrombopoietin Receptor (MPL) Is a Selective Marker for the Identification of Hematopoietic Stem Cells from Myelofibrosis Patients (2016) (0)
Exon-Level Genomic Abnormalities Are Frequent in Cytogenetically Normal Patients with Philadelphia-Chromosome Negative Myeloproliferative Neoplasms (MPNs) (2019) (0)
Effective Management of Patients with Leukemic Transformation of Myelofibrosis. (2009) (0)
Peripheral Blood Karyotyping Is Superior To Bone Marrow and Identifies Most Frequent Structural Chromosomal Rearrangements In Myelofibrosis (2013) (0)
Pharmacological Disruption of the Interplay between HDM2-p53 and NFκB Depletes Myelofibrosis Progenitor/Stem Cells and Dampens the Accompanying Inflammatory Milieu (2022) (0)
malignancies The renaissance of interferon therapy for the treatment of myeloid (2013) (0)
Treatment with Nutlin-3, a Small-Molecule Antagonist of MDM2, in Combination with Low Doses of Pegylated Interferon Alpha 2a Targets Hematopoietic Progenitor Cells From Polycythemia Vera (PV) Patients (2011) (0)
Imetelstat for treatment of myelofibrosis (2017) (0)
Erythroblasts From Polycythemia Vera Patients Express the Dominant negative β Isoform of the Glucocorticoid Receptor. (2009) (0)
Outcome of Allogeneic Stem Cell Transplantation for Patients with Chronic Myelofibrosis and Blastic Transformation of Myelofibrosis (2011) (0)
Distinct Mechanisms Underlying the Ex Vivo Expansion of Human Cord Blood Stem Cells with Different Strategies Currently Used for Allogeneic Transplantation (2019) (0)
The JAK2V617F mutation disrupts the regulated association between calreticulin and the glucocorticoid receptor observed in normal erythroid cells (2015) (0)
Infusion of a Cryopreservable Human Megakaryocyte-Biased Cell Product Results in Sustained Platelet Reconstitution In Vivo (2018) (0)
Combination Treatment with RG7112 and Pegylated Interferon α 2a Specifically Targets JAK2V617F Positive Progenitor Cells From Patients with Myeloproliferative Neoplasms. (2012) (0)
862 IN VITRO STUDIES OF THE PATHOGENESIS OF TRANSIENT ERYTHROBLASTOPENIA OF CHILDHOOD (TEC) (1981) (0)
SDF-1/CXCR4 Interactions in Idiopathic Myelofibrosis. (2005) (0)
The JAK2V617F Mutation Is Present in the Liver Endothelial Cells of Patients with Budd-Chiari Syndrome (2008) (0)
Brief report Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon (cid:1) speciﬁcally targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells (2010) (0)
Chromosomal and FISH Study of 286 Patients with Primary Myelofibrosis (PMF) Reveals Cryptic Abnormalities and Identifies Lesions Associated with Favorable Prognosis and Disease Progression (2011) (0)
Identification of the Origins and Characterization of the Consequences of Megakaryocytic Hyperplasia in Idiopathic Myelofibrosis. (2006) (0)
Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens (2007) (0)
unselected patients Fetal hemoglobin in polycythemia vera: cellular distribution in 50 (2011) (0)
Faculty Opinions recommendation of Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. (2021) (0)
Ex vivo reprogramming of human hematopoietic stem cells is accompanied by increased transcripts of genes regulating metabolic integrity. (2023) (0)
Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials (2020) (0)
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. (2022) (0)
Chapter 69 – Essential Thrombocythemia (2018) (0)
Myelofibrosis Ruxolitinib : The First FDA Approved Therapy for the Treatment of Updated (2012) (0)
Stathmin-Mediated Dysregulation of Microtubules Impairs Megakaryocyte Maturation and Platelet Production (2010) (0)
Single-Cell Multi-Omics Reveals That Pegylated Interferon-Alfa Treatment Differentially Redirects Mutated and Wildtype Hematopoietic Cell Differentiation Trajectories in CALR-mutated Essential Thrombocythemia (ET) Patients (2021) (0)
Oncogenes and the molecular biology revolution in cancer research. (1985) (0)
ASSOCIATION OF 5q- AND REFRACTORY ANEMIA (1977) (0)
228 Erythropoietin and glucocorticoids exert antagonistic effects on STAT-5 phosphorylation in primary human erythroblasts (2008) (0)
Faculty Opinions recommendation of Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. (2021) (0)
does not require marrow stromal cells Generation of human natural killer cells from immature progenitors (2011) (0)
Developing strategies to reduce the duration of therapy for patients with myeloproliferative neoplasms (2020) (0)
therapy Antibody-mediated acquired sideroblastic anemia: response to cytotoxic (2011) (0)
The A3669G Polymorphism of GR Is a Host Genetic Modifier Associated with Polycythemia Vera and Primary Myelofibrosis (2010) (0)
Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis (2022) (0)
Comparable Toxicity between Fludarabine/Full dose i.v. Busulfan and Fludarabine/Melphalan in Allogeneic PBSC Transplantation. (2004) (0)
The New Science and Concepts That Underlie Current and Future Treatments for Myeloproliferative Neoplasms. (2021) (0)
Different Histone Deacetylase Inhibitors Affect Distinct Cellular Targets within the Hierarchy of Hematopoietic Stem / Progenitor Cells. (2005) (0)
Neutophil Gelatinase –Associated Lipocalin (LCN2) Affects Primary Melofibrosis Hematopoietic Progenitor Cells As Well As Microenvironmental Cells (2013) (0)
Regulation of human megakaryocytopoiesis by interacting cytokines. (1990) (0)
The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study. (2016) (0)
Dynamic Changes within Neighborhoods of Genes Expressed by Marrow CD34+ Cells during Recovery from Radiation Injury. (2004) (0)
Myeloproliferative Neoplasm (MPN) Blastic Transformation Occurs at the Level of Both Short and Long Term Hematopoietic Stem Cells (2017) (0)
Effects of hematopoietic growth factors on in vitro colony formation by human megakaryocyte progenitor cells. (1988) (0)
A cDNA data set for expression studies of hematopoietic stem cells: characterization and database mining (2001) (0)
in vitro Parvovirus B19-induced perturbation of human megakaryocytopoiesis (2011) (0)
Valproic Acid Expands the Numbers of HSCs from Cord Blood CD34+ Cells By Linking Epigenetic Modifications to Mitochondrial Remodeling and p53 Upregulation (2016) (0)
In-Vitro and In-Vivo Effects of Autologous and Allogeneic Lymphocytes on Human Cord Blood CD34+ Cell Function. (2004) (0)
Constitutive and hemin enhanced globin gene expression in a human leukemia cell line (1980) (0)
Evidence for the clonal origin of acquired hypomegakaryocytic thrombocytopenic purpura from a sex chromosome mosaic. (1984) (0)
Abstract B072: Immune checkpoint blockade enhances mutated calreticulin-induced T-cell immunity in myeloproliferative neoplasms (2019) (0)
Ontogenic-Specific Increasesin HDAC1 Activity and Transcription Factor Association During the Maturation of Human Adult Erythroblasts in Vitro . (2009) (0)
CD11c+CD86+ cells with direct and indirect antigen-presenting function Allogeneic T cells induce rapid CD34+ cell differentiation into (2013) (0)
Let's not get too JAKed up! (2005) (0)
Chapter 55 – Progress in the Classification of Hematopoietic and Lymphoid Neoplasms: Clinical Implications (2018) (0)
REGULATION OF ERYTHROPOIESIS DURING ERYTHROBLASTIC CRISIS OF JUVLNILE CHRONIC MYELOCYTIC LEUKEMIA (JCML) (1977) (0)
The polycythaemias (2020) (0)
Ex-Vivo Expansion of Marrow Repopulating Cells by Chromatin Modifying Agents Is Associated with Modulation of Expression of Genes Implicated in HSC Self-Renewal. (2006) (0)
African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation. (2005) (0)
Primary Myelofibrosis Is Associated with Truncation of the Plasma Chemokine SDF-1 (2008) (0)
An Altered Microenvironment Within The Spleens Of Patients With Myelofibrosis Affects CD34+ Cell Trafficking (2013) (0)
Initial characterization of a human megakaryocytic leukemia cell line, EST-IU. (1986) (0)
Abstract LB-165: The role of sphingolipid metabolism in the treatment of acute myeloid leukemia (2012) (0)
The CD34+ transcriptosome: Highly expressed genes in human and baboon bone marrow (2000) (0)
cells within chronic myeloid leukemia marrow Identification of BCR/ABL-negative primitive hematopoietic progenitor (2010) (0)
Faculty Opinions recommendation of Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. (2021) (0)
Enriched Populations of Human Megakaryocytic Cells Affect the Behavior of Myelofibrosis CD34+ Cells As Well As Cells Belonging to the MF Supportive Microenvironment (2018) (0)
Faculty Opinions recommendation of Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. (2021) (0)
3119 – DECIPHERING THE IMPACT OF TYPE 1 INTERFERON IN HUMAN CALR-MUTATED AND WILDTYPE HEMATOPOIETIC STEM AND PROGENITOR CELLS IN MYELOPROLIFERATIVE NEOPLASMS VIA SINGLE-CELL MULTI-OMICS (2022) (0)
IDENTIFICATION, CHARACTERIZATION AND MOLECULAR-CLONING OF A NOVEL HUMAN HEMATOPOIETIC-CELL ANTIGEN (HCA) EXPRESSED BY PRIMITIVE HEMATOPOIETIC PROGENITORS (1994) (0)
Pleckstrin-2 is essential for erythropoiesis in β-thalassemic mice, reducing apoptosis and enhancing enucleation (2021) (0)
Type 1 interferon remodels normal and neoplastic hematopoiesis in human (2022) (0)
Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials (2019) (0)
Remembering Ihor Lemischka—The scientist's scientist (2018) (0)
Inhibition of telomerase impairs normal megakaryopoiesis (2014) (0)
Reduced CD26 Dipeptidylpeptidase IV Membrane Expression and Activity of CD34+ Cells from Patients with Myelofibrosis with Myeloid Metaplasia. (2006) (0)
Faculty Opinions recommendation of The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts. (2021) (0)
Co-Cultivation of MF CD34+ Cells with Microenvironmental Cells Has a Profound Effect on MF Hematopoiesis and Responses to Drug Therapy (2022) (0)
CD34+CD90+ Cord Blood Cells Which Have Undergone Multiple Cell Divisions Retain Marrow Repopulating Potential. (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronald Hoffman?

Ronald Hoffman is affiliated with the following schools: